2023-11-03Zeitschriftenartikel
Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic
dc.contributor.author | Prins, Henrieke | |
dc.contributor.author | Dörre, Achim | |
dc.contributor.author | Schmidt, Daniel | |
dc.date.accessioned | 2025-08-26T10:05:43Z | |
dc.date.available | 2025-08-26T10:05:43Z | |
dc.date.issued | 2023-11-03 | none |
dc.identifier.other | 10.3389/fphar.2023.1241310 | |
dc.identifier.uri | http://edoc.rki.de/176904/12914 | |
dc.description.abstract | Background: In 2019, Germany introduced a law to reimburse high-incidence populations for pre-exposure prophylaxis (PrEP), prescribed as tenofovir-disoproxil/emtricitabine (TDF/FTC), via statutory health insurance (SHI). We studied changes in TDF/FTC-prescriptions after the implementation of this law and during the COVID-19 pandemic. Methods: We performed an interrupted time series analysis with monthly prescriptions per defined time period as the outcome. We considered the introduction of SHI-covered PrEP (09/2019) as an interruption, and four COVID-19 waves and two national lockdowns (2020–2021) as explanatory variables. We extrapolated prescriptions had the lockdowns not occurred, and compared this to the actual prescriptions. We performed sub-analyses based on stratification by five federal states with the highest proportion of PrEP users. We assessed the models’ goodness-of-fit based on the adjusted R-squared using RStudio. Results: The best fitting model included SHI-covered PrEP and the first COVID-19 lockdown (04/2020). The decrease in prescriptions during the first lockdown was significant nationally, and in the five federal states for single-month prescriptions. The first lockdown resulted in reductions of 57.7% (95% prediction interval (PI): 23.0%–92.4%) for single-month prescriptions, while 17.4% (95% PI: 0.28%–34.5%) nationally, and 13.9% (95% PI: -3.67%–31.5%) for 3-month prescriptions. Conclusion: Introduction of SHI-covered PrEP resulted in a doubling of TDF/FTC-prescriptions nationwide in the first month alone. A drop in prescriptions was most apparent after the first lockdown, and particularly affected PrEP initiations, possibly due to reduced healthcare access and behavioural changes. Ongoing monitoring of TDF/FTC-prescriptions is needed to safeguard access to preventative care such as PrEP and particularly PrEP initiation during public health crises like COVID-19. | eng |
dc.language.iso | eng | none |
dc.publisher | Robert Koch-Institut | |
dc.rights | (CC BY 3.0 DE) Namensnennung 3.0 Deutschland | ger |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/de/ | |
dc.subject | pre-exposure prophylaxis (PrEP) | eng |
dc.subject | pharmacy prescriptions | eng |
dc.subject | COVID-19 | eng |
dc.subject | lockdown | eng |
dc.subject | Germany | eng |
dc.subject.ddc | 610 Medizin und Gesundheit | none |
dc.title | Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic | none |
dc.type | article | |
dc.identifier.urn | urn:nbn:de:0257-176904/12914-7 | |
dc.type.version | publishedVersion | none |
local.edoc.container-title | Frontiers in Pharmacology | none |
local.edoc.type-name | Zeitschriftenartikel | |
local.edoc.container-type | periodical | |
local.edoc.container-type-name | Zeitschrift | |
local.edoc.container-publisher-name | Frontiers Media S.A. | none |
local.edoc.container-reportyear | 2023 | none |
local.edoc.container-firstpage | 01 | none |
local.edoc.container-lastpage | 10 | none |
dc.description.version | Peer Reviewed | none |